LikeMinds seeks to develop prognostic and diagnostic tools to improve the diagnosis and subsequent management options for degenerative brain diseases with more accurate and definitive diagnosis and monitoring of brain health.– –
OUR MISSION IS TO HELP MAKE SOMEDAY HAPPEN.
SOMEDAY DOCTORS WILL DETECT PARKINSON’S DISEASE YEARS BEFORE THE FIRST TREMOR.
SOMEDAY DOCTORS WILL DETECT PARKINSON’S DISEASE YEARS BEFORE THE FIRST TREMOR.
OUR MISSION IS TO HELP MAKE SOMEDAY HAPPEN.
The need for more accurate, timely and definitive diagnoses– –
Diagnostic precision in imaging is critical to the diagnosis and subsequent treatment of degenerative brain disorders such as Parkinson’s disease, dementia and other dopamine-related disorders. Accurate screening today remains elusive. Clinical diagnosis alone results in diagnostic error rates of 50 – 74 percent in the five years following a patient’s first tremor by which time appropriate interventions and drug therapies are limited[1].
The brain frontier– –
More than 13 million people are impacted by tremor-related brain disorders today, and these rates are expected to rise as Baby Boomers continue to age. The estimated cost of caring for those with neurological diseases will increase from $500 billion today to over $1 trillion by 2050, more than heart disease and cancer combined[2].
Our mission: clarity when it counts– –
LikeMinds is a radiopharmaceutical product and technology development company that aims to provide a precise, early, accurate and ultimately actionable diagnosis of Parkinson’s Syndrome, dementia and other dopamine-related brain diseases. Our experimental DaT2020TM imaging agent product candidate is being investigated in a Phase 2b/3 clinical study intended to measure efficacy and success rates in diagnosing and characterizing dopamine receptor activity in the brain.
At LikeMinds, we view a patient’s tremor as the external symptom of a disease sparked long before its first clinical symptoms with a nearly undetectable, yet measurable dip in a brain’s ability to generate and receive normal brain cell signals. Along the way that story of an emerging brain disease may offer a series of moments, all chartable and trackable and many representing opportunities for care and intervention.
We’re passionately focused on helping clinicians see and mark that moment, offering clarity and precision, hopefully and possibly a long time before symptoms appear.
[1] Neurology, 2014 Jul 29: 83(5) 406-412 Charles H. Adler et al
Low clinical diagnostic accuracy of early vs advanced Parkinson disease.
[2] McGovern Institute for Brain Research at MIT
Brain Disorders: By The Numbers
